Page 19 - Solid Tumors News Today

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CRC--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progres...

Bristol Myers Squibb today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable metastatic...

Faron Pharmaceuticals Ltd.     Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine ...

Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse effectsBexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceuti...

BOTHELL - Seagen Inc. today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-drug conjugate ado-trastuzumab emtansine . The combination showed...

07.12.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for ...

/PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative...

BOTHELL, Wash.--(BUSINESS WIRE)--Dec 6, 2023--

Merck a leading science and technology company today announced a license agreement with Abbisko Therapeutics Co. Ltd. Shanghai China for pimicotinib ABSK021 which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor TGCT.

– STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck – – Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated...